

REFERENCES

- Abbasi F, Brown BWB, Lamendola C, McLaughlin T, Reaven GM.** Relationship between obesity, insulin resistance, and coronary heart disease risk. *J Am Coll Cardiol* 2002;40:937-943.
- Alberti KG, Zimmet PZ.** Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15: 539-53.
- AD.** Hepatic uptake of chylomicron remnants. *J Lipid Res* 1997;38:2173–92.
- Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, Morris DV, Price J, Jacobs HS.** Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. *Lancet* 1985;2:1375–1379.
- Adams J, Polson DW, Franks S.** Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. *Br Med J (Clin Res Ed)* 1986; 293 : 355-359.
- Adashi E A, Resnick C E, Svoboda M E, Jones G S.** Somatomedin c enhances induction of LH receptors by FSH in cultured rat granulosa cells. *Endocrinology* 1981; 116 : 2369.
- Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, et al.** High prevalence of metabolic syndrome in Mexico. *Arch Med Res* 2004;35:176-181.
- Aleem F A and McIntoch T.** Elevated plasma levels of B endorphins in a group of women with polycystic ovarian disease. *Fertil Steril* 1984; 42 : 680.
- American Diabetes Association position statement:** evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. American Diabetes Association Task Force for Writing Nutrition Principles and Recommendations for the Management of Diabetes and Related Complications. *J Am Diet Assoc.* 2002; 102: 109–118.

- American Diabetes Association.** Screening for type 2 diabetes. *Diabetes Care* 2004;27:Suppl 1:S11-S14.
- Ancien P, Quereda F, Matallin P, Villarroya E., Kopez-Fernandez J A.** *Fertil Steril* 1999; 32 : 40 – 72.
- Anderson JL, Horne BD, Jones HU, et al.** for the intermountain heart collaborative (IHC) study. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? *Cardiology* 2004;101:185–93.
- Anttila, L., Koskinen, P., Jaatinen, T.A., Erkkola, R., Irjala, K. & Ruutiainen, K.** Insulin hypersecretion together with high luteinizing hormone concentration augments androgen secretion in oral glucose tolerance test in women with polycystic ovarian disease. *Hum Reprod* 1993 ; 8: 1179-1183.
- Arai T, Yamashita S, Hirano K, et al.** Increased plasma cholesteryl ester transfer protein in obese subjects: a possible mechanism for the reduction of serum HDL cholesterol levels in obesity. *Arterioscler Thromb* 1994;14:1129–36.
- Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG.** The plasminogen activator system in women with polycystic ovary syndrome. *Fertil Steril* 1998;69:236-241.
- Attia GR, Rainey WE, Carr BR.** Metformin directly inhibits androgen production in human thecal cells. *Fertil Steril* 2001;76:517-524.
- Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, et al.** Low-density lipoprotein particle size, triglycerides, and highdensity lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. *Am J Cardiol* 2000; 86: 412-6.
- Austin MA, Hokanson JE, Edwards KI.** Hypertriglyceridemia as a cardiovascular risk factor. *Am J Cardiol* 1998;81(4A):7B-12B.
- Ayyobi AF, Brunzell JD.** Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. *Am J Cardiol* 2003;92:27–33J.

Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. *J Clin Endocrinol Metab* 1994;78:810–815.

Azziz R, Ehrmann D, Legro R S. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. *J Clin Endocrinol Metab* 2001;86:1626-1632.

Baird D T, Corker C S, Davidson D W, Hunter W M, and Michie E A. Pituitary ovarian relationships in polycystic ovary syndrome. *Journal of Endocrinology and Metabolism* 1977; 45 : 798.

Balen A H, Conway G S, Kaltsas K. J . Polycystic ovary syndrome. The spectrum disorder in 1741 patients. *Human Reprod* 1995; 10 : 2197 – 2111.

Balen A. Polycystic ovary syndrome and cancer. *Hum Reprod Update* 2001;7:522-525.

Balkau B, Charles MA, Drivsholm T, et al. European Group for the study of insulin resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. *Diabetes Metab* 2002;28:364–76.

Baranao J and Hammond JM. Comparative effects of insulin and insulin like growth factors on DNA synthesizes and differentiation of porein granulose cells. *Biochemical And Biophysical Research communications* 1984; 124 : 484 – 490.

Baranaociska B, Radzikowska M, wasilewska, Dziubinski E, Kaplinski A, Roguski K. polycystic ovary syndrome. *Gynecol Endocrinol* 1999; 13 : 344 – 351.

Barbieri RL, and Ryan KJ. Effects of insulin on steroidogenesis in cultured poreine ovarian theca. *Fertil Steril* 1983; 40 : 237.

Barbieri R C, Markis A, Randall R W, Daniels G, Kistner R W. Insulin stimulates androgen accumulation in incubations of ovarian stroma from women with hyperandrogenism. *J Clin Endocrinol Metab* 1986; 62 : 904 – 910.

Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. *Diabet Med* 1999; 16:442–443.

- Barreca A, Minuto F, and Volpe.** Insulin like growth factors and IGF_I binding protein in the follicular fluids of growth hormone treated patients. *Clin Endocrinol* 1990; 32 : 497.
- Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T.** Regulation of androgen production in cultured human thecal cells by IGF-1 and insulin. *Fertil Steril* 1993; 59: 323-331.
- Behrman S J, Kistner R W, and Patton G W, (eds).** Progress in infertility 3 rd edn. *Boston, MA: Little, Brown* 1998.
- Belli SH, Graffigna MN, Oneto A, Otero P, Schurman L, Levalle OA.** Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. *Fertil Steril* 2004;81:624-629.
- Beltowski J .** Adiponectin and resistin--new hormones of white adipose tissue. *Med Sci Monit* 2003;9:RA55–61.
- Bergen C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T.** Regulation of androgen production in cultured human thecal cells by IGF-1 and insulin. *Fertil Steril* 1993; 59: 323-331.
- Birdsall MA, Farquhar CM, White HD.** Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. *Ann Intern Med* 1997;126:32–35.
- Boden G .** Fatty acids and insulin resistance. *Diabetes Care* 1996;19:394–5.
- Borch-Johnsen K, Colagiuri S, Balkau B, Glumer C, Carstensen B, Ramachandran A, et al.** Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. *Diabetologia* 2004;47:1396-1402.
- Bouchard, C., Despres, J.P. & Mauriege, P.** Genetic and nongenetic determinants of regional fat distribution. *Endocr Rev* 1993;14: 72-93.
- Bracero N, Zacur HA.** Polycystic ovary syndrome and hyperprolactinemia. *Obstet Gynecol Clin North Am* 2001;28:77–84.
- Bruno G, Merletti F, Biggeri A, Bargerò G, Ferrero S, Runzo C, et al.** Metabolic syndrome as a predictor of all-cause and cardiovascular

mortality in type 2 diabetes. The Casale Monferrato Study. *Diabetes Care* 2004;27:2689-2694.

Buffington, C.K. & Kitabchi, A.E. Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome. *Metab Clin Exp* 1994;43: 1367-1372.

Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. *J Clin Endocrinol Metab* 1980; 50 : 113 – 6.

Buyalas RP, and Lee CT. polycystic ovarian syndrome: pathophysiology and outcome with invitro fertilization. *Fertil Steril* 1996; 65 : 120.

Cara JF, Rosenfield RD. Insulin like growth factor-1 and insulin potentiate LH-induced androgen synthesis by rat ovarian thecal-interstitial cells. *Endocrinology* 1988; 123 : 733 – 739.

Carey AH, Chan KL, Short F, White D, Williamson R, Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. *Clin Endocrinol* 1993; 38: 653-658.

Carina E, Gonzalez F, Chang L. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. *Obstet Gynecol* 1995; 85 : 971 – 976.

Carmina E, Rosato F, Maggiore M, Gagliano A M, Idovina D, and Janni A. Prolactin secretion in polycystic ovary syndrome : Correlation with steroid pattern. *Acta Endocrinologica (Copenh)* 1995; 105 : 99.

Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. *Hum Reprod* 2003;18:2289-2293.

Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E. The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance. *Diabetes Care* 2003;26:1333–1337.

Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome : lower prevalence in Souther

Italy than in USA and the influence of criteria for the diagnosis of PCOS. *Eur J Endocrinol* 2006; 154: 141-5.

Cataldo NA. Insulin like growth factor binding proteins: do they play a role in polycystic ovary syndrome? *Endocrinology* 1997; 15: 123-136.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the *JNC 7 report. JAMA* 2003; 289:2560–257.

Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. *Am J Med* 1993;94:350–6.

Chang R J, Mandel F P, Lu J K, and Jud H L. Enhanced disparity of gonadotropins secretion by estrone in women with polycystic ovarian disease. *J Clin Endocrinol Metab* 1982; 54 : 590.

Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. *J Clin Endocrinol Metab* 1983; 57 : 356–359.

Cheng T. Metabolic syndrome in China. *Circulation* 2004;109:e180.

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. *JAMA.* 2003; 289: 2560–2572. *Erratum in: JAMA.* 2003;290:197.

Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF II, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;88:2562-2568.

- Ciampelli, M., Fulghesu, A.M., Cucinelli, F., Pavone, V., Caruso, A., Mancuso, S. & Lanzone, A** Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. *Hum Reprod* 1997; 12: 1897-1901.
- Ciaraldi TP.** The role of adenosine in insulin action coupling in rat adipocytes. *Mol Cell Endocrinol.* 1988; 60:31–41.
- Ciaraldi TP, Hickman M, Morales AJ, Yen SSC, Olefsky JM.** Cellular specificity of insulin resistance in polycystic ovary syndrome. *Endocrinology.* 1995; 136(Suppl 1):179.
- Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report.** National Institutes of Health. *Obes Res.* 1998; 2 (suppl 6): 51S–209S. *Erratum in: Obes Res.* 1998; 6: 464.
- Couillard C, Bergeron N, Prud'homme D, et al.** Postprandial triglyceride response in visceral obesity in men. *Diabetes* 1998;47:953–60.
- Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M.** Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. *J Clin Endocrinol Metab* 1995;80:2057-2062.
- Conway GS, Agrawal R, Betteridge DJ, et al.** Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)*.1990; 37:119–125.
- Conway GS, Agrawal R, Betteridge DJ and Jacobs.** Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 1993; 37 : 119 – 125.
- Cumming D C, Quiolgey M E, Rebar R W, and Yen S S C.** Reduced hypothalamic influences on LH secretion in polycystic ovarian disease. *Fertil Steril* 1981; 36 : 431.
- Cummings MH, Watts GF, Umpleby AM, et al.** Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. *Diabetes* 1995;44:1059–65.
- Dahlgreen E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, et al.** Women with polycystic ovary syndrome wedge resected in

1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. *Fertil Steril* 1992; 57: 505-513.

DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose Tolerance and Cardiovascular Mortality. Comparison of fasting and 2-hour diagnostic criteria. *Arch Intern Med* 2001;161:397-404.

DeFronzo, R.A., Bonadonna, R.C. & Ferrannini, E. Pathogenesis of NIDDM. A balanced overview. *Diabetes Care* 1992; 15: 318-368.

Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. *N Engl J Med* 1994;331:968–973.

Despres JP, Moorjani S, Lupein P, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins and cardiovascular disease. *Arteriosclerosis* 1990; 10: 497-511.

Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004;89:1273-1276.

Diamanti-Kandarakis E, Kouli C., Bergiele A. A survey of the polycystic ovary syndrome in the greek island of Lesbos: hormonal and metabolic profile. *J Clin Endocrinol Metabol* 1999; 84 : 4006 – 4011.

Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of the human cholesteryl ester transfer protein cDNA. *Nature* 1987;327:632–4.

Drop, S.L. Report on the nomenclature of the IGF binding proteins. *Acta Endocrinol* 1991; 125: 707-708.

Dror Meirow, Itamar Raz, Yossepowitch O, Brzeinski A, Rosler A, Berry M E, Schendler G. Dyslipidemia in polycystic ovary syndrome : different types, different etiologies. *Hum Reprod* 1996; 11 : 1848 – 1853.

- Dunaif A, Futterweti W, Mandeli J.** Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. *J Clin Endocrinol Metab* 1987; 65 : 499 – 507.
- Dunaif A, Futterweit W, Dobrjansky A.** Profound insulin resistance, independent of obesity in polycystic ovary syndrome. *Diabetes* 1989; 38 : 1165 – 1174.
- Dunaif A, Green G, Futterweit W, & Dobrjansky A.** Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1990; 70: 699-704.
- Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L** Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. *J Clin Endocrinol Metab* 1991; 73:590–595.
- Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T** Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. *Diabetes* 1992; 41:1257–1266.
- Dunaif A, Sorbara L, Delson R, Green G.** Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. *Diabetes* 1993;42:1462-1468.
- Dunaif A** Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. *Am J Med* 1995; 98:33S–39S.
- Dunaif A, Xia J, Book CB, Schenker E, Tang Z.** Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. *J Clin Invest* 1995;96:801-10.
- Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R.** The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. *J Clin Endocrinol Metab* 1996;81:3299-3306.

- Dunaif A.** Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev* 1997;18:774-800.
- Dunaif A.** Insulin action in polycystic ovary syndrome. *Endocrinol Metab Clin North Am* 1999; 28 : 341 – 359.
- Dunaif A, Thomas A.** Current concepts in the polycystic ovary syndrome. *Annu Rev Med* 2001;52:401–419.
- Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E.** Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). *Am J Physiol Endocrinol Metab* 2001;281:E392-E399.
- Eagleson CA, Gingrich MB, Pastor CL, et al.** Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. *J Clin Endocrinol Metab* 2000;85:4047-4052.
- Edman C D, and MacDonald P C.** Effect of obesity on conversion of androstendione to esterone in ovulatory and anovulatory young women. *Am J of Obstet Gynecol* 1988; 130 : 456.
- Ehrmann D, Rosenfield R, Barnes RB, Brigell DF, Sheikh Z.** Detection of functional ovarian hyperandrogenism in women with androgen excess. *N Engl J Med* 1992; 327 : 157-162.
- Ehrmann DA, Sturis J, Byrne MM et al.** Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. *J Clin Immunol* 1995; 96: 520-527.
- Ehrmann DA.** Obesity and glucose intolerance in androgen excess. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen excess disorders in women. *Philadelphia: Lippincott-Raven, 1997:705-12.*
- Ehrmann D, Cavaghan M, Imperial J, Sturis J, Rosenfield R, Polonsky K.** Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1997; 82: 524-530..

Ehrmann, D.A. Insulin resistance. Its role in the pathogenesis of PCOS. Thirty-second Annual Postgraduate Program. Polycystic Ovary Syndrome: fertility issues and beyond. Toronto, Ontario, Canada. **American Society for Reproductive Medicine 1999; 51-58.**

Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. ***Diabetes Care* 1999; 22 : 141-146.**

Ehrmann D A, Breda E, Cavaghan M K. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. ***Diabetologia* 2002;45:509-517.**

Ehrmann D A, Breda E, Corcoran M C. Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome. ***Am J Physiol Endocrinol Metab* 2004;287:E241-E246.**

Eisner JR, Dumesic DA, Kemnitz JW, Colman RJ, Abbott DH. Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestation. ***Obes Res* 2003; 11 : 279-286.**

Ericson G F, Hsueh A J, Wuigley M E, Rebar R W, and Yen S S C. Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries. ***J Clin Endocrinol Metab* 1979; 49 : 514.**

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). ***JAMA* 2001; 285:2486–2497.**

Evans D J, Hoffman R G, and Kalkoff R K. Relationship of androgenic activity to body fat topography fat cell morphology and metabolic aberrations in premenopausal women. ***J Clin Endocrinol Metab* 1983; 57 : 304.**

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. ***Diabetes Care* 2003;11:3160-3167.**

Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. ***J Clin Endocrinol Metab* 2001;86:3574-3578.**

- Farquhar C, Birdsall, Manning P, Mitchell J, and France J.** The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. *Aus N Z J Obstet Gynecol* 1994; 34:67.
- Farrell S, Cheng YJ, Blair SN.** Prevalence of the metabolic syndrome across cardiorespiratory fitness levels in women. *Obes Res* 2004;12:824-830.
- Ferrannini, E., Barrett, E.J., Bevilacqua, S. & DeFronzo, R.A.** Effect of fatty acids on glucose production and utilization in man. *J Clin Invest* 1983; 72: 1737-1747.
- Ferrannini, E. & Groop, L.C.** Hepatic glucose production in insulin-resistant states. *Diabetes Metab Rev* 1989; 5: 711-726.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)** Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486–2497.
- Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP.** Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2001;86:1175-1180.
- Fontbonne AM, Eschwege EM.** Insulin and cardiovascular disease. Paris Prospective Study. *Diabetes Care* 1991; 14: 461-9.
- Ford ES, Giles WH, Dietz WH** Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; 287:356–359.
- Ford ES, Mokdad AH, Giles WH.** Trends in waist circumference among U.S. adults. *Obes Res* 2003;11:1223-1231.
- Ford ES, Giles WH** A comparison of the prevalence of the metabolic syndrome using two proposed definitions. *Diabetes Care* 2003; 26:575–581.

- Franks S, Adams J, Mason H D, and Polson D W.** Ovulatory disorders in women with polycystic ovary syndrome. *Clinics in Obstetric and Gynecology* 1985; 12(3) : 605 – 627.
- Franks S.** Polycystic ovary syndrome: a changing perspective. *Clin Endocrinol (Oxf)* 1989;31:87–120.
- Franks S D, Kiddy P, Sharp A, et al.** Obesity and polycystic ovary syndrome. *Ann NY Acad Sci* 1991; 626 : 201–206.
- Frank S.** Polycystic ovary syndrome. *N Engl J Med* 1995; 333: 853-861..
- Franks S.** Adult polycystic ovary syndrome begins in childhood. *Best Pract Res Clin Endocrinol Metab* 2002; 16 : 263-272.
- Fruzzetti F Del-orenzo, Ricci C, and Teti G.** Ovarian influence on adrenal androgen secretion in polycystic ovarian disease. *Fertil Steril* 1995; 63 : 734 – 741.
- Futterweit W.** Polycystic ovarian disease, springer-Verlag. *New York* 1984; 163.
- Gazino JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE.** Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. *Circulation* 1997; 96 : 2520 – 5.
- Genest JG Jr.** Dyslipidemia and coronary artery disease. *Can J Cardiol* 2000;16 (suppl A) :3–4A.
- Genuth S, Alberti KG, Bennett P, et al.** Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 2003; 26: 3160–3167.
- Gilling C, Smith and Stephen F.** Polycystic ovary syndrome. *Reproduction medicine review* 1993; 2 : 15 – 32.
- Ginsberg HN, Le N-A, Goldberg IJ, et al.** Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and AI: evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. *J Clin Invest* 1986;78:1287–95.

Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. *J Cardiovasc Risk* 2000;7:325–31.

Giudice, L.C. Insulin-like growth factors and ovarian follicular development. *Endocr Rev* 1992; 13: 641-669.

Giudice, L.C. Growth factor action on ovarian function in polycystic ovary syndrome. *Endocrinol Metab Clin N Am* 1999; 28: 325-339, vi.

Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. *Fertil Steril* 2001;75:46-52.

Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. *Fertil Steril* 2002;77:520-525.

Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism* 2003;52:908-915.

Glueck CJ, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. *Hum Reprod* 2004;19:1323-1330.

Goldberg R B, Rabin D, Alexander A N, Doelle G C, Getz G S. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol, and apoprotein A-1, and B. *J Clin Endocrinol Metab* 1985; 60 : 203 – 207.

Goldstein J, Schrott H, Hazzard W. Hyperlipidemia in coronary heart disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. *J Clin Invest* 1973;52:1544–68.

- Goldstein BJ.** Insulin resistance: from benign to type 2 diabetes mellitus. *Rev Cardiovasc Med* 2003;4:S3–10.
- Gonzalez F.** Adrenal involvement in polycystic ovary syndrome. *Semin Reprod Endocrinol* 1997; 15: 137-157.
- Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al.** Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *J Clin Oncol* 2002;20:42-51.
- Gopal M, Duntley S, Uhles M, Attarian H.** The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovary syndrome. *Sleep Med* 2002;3:401-4.
- Gorden DJ, Rifkind BM.** High density lipoprotein – the clinical implication of recent studies. *N. English J Med* 1989; 321:1311 – 1316.
- Gorter PM, Olijhoek JK, van der Graaf Y, et al.** SMART Study Group. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. *Atherosclerosis* 2004;173:363–9.
- Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, et al.** Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. *Atherosclerosis* 1994; 106: 241-53.
- Groop L, Orho-Melander M.** The dysmetabolic syndrome. *J Intern Med* 2001; 250: 105-20.
- Green AG, Milligan G, Dobias SB.** Gi down-regulation as a mechanism for heterologous desensitization in adipocytes. *J Biol Chem.* 1992; 267:3223–3229.
- Grundy SM, Brewer HB, Jr, Cleeman JI, Smith SC, Jr, Lenfant C, .** American Heart Association. National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004;109:433-438.

Haffner SM, Lehto S, Ronnema T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229–34.

Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome . *Diabetes* 1992; 41 : 715 – 722.

Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. *Am J Med* 2003; 115 (Suppl 8A): 6S-11S.

Haffner SM, D’Agostino Jr R, Festa A, Bergman RN, Mykkanen L, Karter A, Saad MF, Wagenknecht LE Low insulin sensitivity ($S(i) = 0$) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors? *Diabetes Care* 2003; 26:2796–2803.

Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. *Diabetes Care* 1998; 21:518–524.

Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. *Clin Endocrinol (Oxf)*.1994; 41:463–471.

Haisenleder DJ, Dalkin AC, Ortolano GA, Marshall JC, Shupnik MA. A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. *Endocrinology* 1991;128:509-517.

Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. *Physiol Res* 2004;53:123–9.

Hamilton-Fairley D, and Pearce J. Polycystic ovary syndrome. In ASCHR< Studd J. editors. *Annual progress in reproductive medicine* 1993; pp 71.

- Hanin R V Jr, Carlson I H, Flood C A.** Metabolism of dihydroepiandrosterone sulfate (DS) in normal women and women with high DS concentrations. *J Clin Endocrinol Metab* 1991; 73 : 1210 – 1215.
- Hardiman P, Pillay OC, Atiomo W.** Polycystic ovary syndrome and endometrial carcinoma. *Lancet* 2003;361:1810-1812. [Erratum, *Lancet* 2003;362:1082.]
- Hershalg A, and Peterson C M.** Endocrine disorders. In Berek JS, Adashi EY, Hillard PA editors. Novak's Gynecology "12th edition". *Baltimore Maryland : Williams and Wilkins* 1996; 837.
- Herzog A, Seibel M M, Schaner D, Vaitukaitis J L, and Geshwind N.** Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. *Arch Neurology* 1986; 43 : 347.
- Hill, P., Garbaczewski, L., Helman, P., Huskisson, J., Sporangisa, E. & Wynder, E.L.** Diet, lifestyle, and menstrual activity. *Am J Clin Nutr* 1980; 33: 1192-1198.
- Hoffman D L, Klove K, and Lobo R A .** The prevalence and the significance of the elevated dehydroepiandrosterone sulfate in anovulatory women. *Fertil. Steril* 1984; 42: 76-81
- Holmang, A., Larsson, B.M., Brzezinska, Z. & Bjorntorp P.** Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. *Am J Physiol* 1992; 262: E851- 855.
- Holt V, Muller O A, and Fabbush R.** β -endorphin in human plasma. Basal and pathologically elevated levels. *Life Sci* 1979; 25 : 37.
- Holte J, Bergh T, Berne C, Berglund L, Lithell H.** Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. *J Clin Endocrinol Metab* 1994; 78 : 1052–1058.
- Holte, J., Bergh, T., Berne, C., Berglund, L. & Lithell, H.** Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. *J Clin Endocrinol Metab* 1994a; 78: 1052-1058.

Holte, J., Bergh, T., Gennarelli, G. & Wide, L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. *Clin Endocrinol* 1994b; 41: 473-481.

Holte J, Bergh T, Berne C et al. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome, *J Clin Endocrinol Metab* 1995; 80: 2586-2593.

Holte, J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. *Baillieres Clin Endocrinol Metabolism* 1996; 10: 221-247.

Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with polycystic ovarian syndrome. *Clin Endocrinol* 1998; 41 : 463 – 471.

Legro RS, Kunselman AR, Dunaif A: Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am J Med* 111:607–613, 2001

Holte J, Bergh T, Berne C, Lithell H: Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. *Clin Endocrinol (Oxf)* 41:463–471, 1994

Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. *Hum Reprod* 2002;17:2495–2499.

Hsia J, Bittner V, Tripputi M, et al. Metabolic syndrome and coronary angiographic disease progression: the women's angiographic vitamin and estrogen trial. *Am Heart J* 2003;146:439–45.

Hulley SB, Roseman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. *N Engl J Med* 1980;302:1383-1389

Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. *Clin Endocrinol (Oxf)* 2001; 5 : 667-672.

- Ilanne-Parikka P, Erickson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laasko M, et al.** Finnish Diabetes Prevention Study Group. Prevalence of the metabolic syndrome and its components: findings from Finnish general population sample and the Diabetes Prevention Study cohort. *Diabetes Care* 2004;27:2135-2140.
- Insler V, and Lunenfield B.** Pathophysiology of Polycystic ovary syndrome. *New insight. Hum Reprod* 1991; 6 : 1025.
- Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L:** Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 24:683–689, 2001.
- Jahanfer S, Eden J A, Nguyen T.** A twin study of polycystic ovary syndrome. *Fertil Steril* 1995; 63 :3.
- Jeppesen J, Hein HO, Suadicani P, Gynelberg F.** High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. *Hypertension* 2000;36:226-239.
- Jeppesen J, Hollenbeck CB, Zhou M-Y, Coulston AM, Jones C, Chen Y-DI, et al.** Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. *Arterioscler Thromb Vasc Biol* 1995;15:320-324.
- Ji Q, Ikegami H, Fujisawa T, et al.** A common polymorphism of uncoupling protein 2 gene is associated with hypertension. *J Hypertens* 2004;22:97–102.
- Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D.** Ultrasound examination of polycystic ovaries: is it worth counting the follicles? *Hum Reprod* 2003;18:598–603.
- Judd H L, Mephreson R A, Pakoff J S, Jud S S C.** Correlation of the effects of dexamethasone administration on the urinary 17-ketosteroid and serum androgen levels in patients with hirsutism. *Am J Obstet Gynecol* 1982; 59 : 680.
- Kahn SE, Prigeon RL, McCulloch DK.** Quantification of the relationship between insulin sensitivity and B-cell function in human

subjects: evidence for a hyperbolic function. *Diabetes* 1993;42:1663-1672.

Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. *JAMA* 1996;275:1571-1576.

Kauffman M, Pinsky L, and Feder-Hollander. Defective upregulation of the androgen receptors in human androgen insensitivity. *Nature* 1981; 297 : 735.

Kauffman RP, Baker VM, DiMarino P, Gimpel T, Castracane VD. Polycystic ovarian syndrome and insulin resistance in white and mexican american women: a comparison of two distinct population. *Am J Obstet Gynecol* 2002; 187: 1362 – 1369.

Kelly CJG, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JMC. Altered vascular function in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2002;87:742-746.

Kiddy, D.S., Hamilton-Fairley, D., Seppala, M., Koistinen, R., James, V.H., Reed, M.J. & Franks, S. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor- I. *Clin Endocrinol* 1989; 31: 757-763.

Kim SH, Abbasi F, Reaven GM. Impact of degree of obesity on surrogate estimates of insulin resistance. *Diabetes Care* 2002;27:1998-2002.

Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. *Diabetes Vasc Dis Res* 2004;1:68-76.

Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. *Psychosom Med* 2004;66:316-322.

Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)*. 1992; 36:105–111.

- Kirschner MA, Samojilik E, Drejda M, Szmal E, Schneider G, Ertel N.** Androgen – estrogen metabolism in women with upper body versus lower body obesity. *J Clin Endocrinol Metab* 1990; 70 : 473 – 9.
- Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R** Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *J Clin Endocrinol Metab* 1998; 83:3078–3082.
- Korhonen S, Hippelainen M, Vanhala M, Heinonen S, Niskanen L** The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. *Fertil Steril* 2003; 79:1327–1334.
- Knowler WC, Barrett-Connor E, Fowler SE, et al.** Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393-403.
- Kolovou G, Anagnostopoulou K, Pilatis N, et al.** Heterozygote men with familial hypercholesterolaemia (FH) may have an abnormal triglyceride response postprandially. Evidence for another predictor of vascular risk in FH. *Int J Clin Practice* 2005;59:311–17.
- Kolovou G, Cokkinos DV.** Low serum levels of high-density lipoprotein cholesterol and hypolipidaemic treatment. *Curr Med Res Opin* 2002;18:265–8.
- Kolovou G, Daskalova D, Petropoulos I, et al.** Effect of baseline levels on response of high density lipoprotein cholesterol to hypolipidemic treatment. *Am J Cardiol* 2003;92:1339–42.
- Kolovou GD, Daskalova D, Iraklianiou SA, et al.** Postprandial lipemia in hypertension. *J Am Coll Nutr* 2003;22:80–7.
- Koopmans SJ, Sips HCM, Bosman J, Radder JK, Krans HMJ.** Antilipolytic action of insulin in adipocytes from starved and diabetic rats during adenosine-controlled incubations. *Endocrinology*. 1989; 125:3044–3050.
- Kousta E, Cela E, Lawrence N.** The prevalence of polycystic ovaries in women with a history of gestational diabetes. *Clin Endocrinol (Oxf)* 2000;53:501-507.

Krosnick A. The diabetes and obesity epidemic among the Pima Indians. *N J Med* 2000; 97: 31 – 37.

Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or = 50 years) and women (<or = 60 years) with coronary arterydisease. *Am J Cardiol* 1993;71:631–9.

Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. *Am J Cardiol* 2002;90:30–47i.

Laatikainen, T., Anttila, L., Suikkari, A.M., Ruutiainen, K., Erkkola, R. & Seppala, M. Effect of naloxone on plasma insulin, insulin-like growth factor I, and its binding protein 1 in patients with polycystic ovarian disease. *Fertil Steril* 1990; 54: 434-437.

Lachein G C, Barnett M S, and Hopper B R. Adrenal functions in normal women and women with Polycystic ovary syndrome. *J Clin Endocrinol Metab* 1979; 49 : 892.

Lachelin G C L. The Polycystic ovary syndrome. In : Progress in Obstetric and gynecology. Studd J. (ed). *Churchill Livingstone* 1984; 4 : 290 – 299.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002; 288:2709–2716.

Lakka HM, Lakka TA, Tuomilehto J, et al. Abdominal obesity is associated with increased risk of acute coronary events in men. *Eur Heart J* 2002;23:706–13.

Lee KW, Ayyobi AF, Frohlich JJ, et al. APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FER(HDL) but is not a risk factor for coronary artery disease. *Atherosclerosis* 2004;176:165–72.

Lefbvre P, Binger J, Renard E. Infulences of body weight fat pattern and nutrition on the management of PCOS. *Hum Reprod* 1997; 12 (Suppl 1) : 72 – 81.

- Legro RS.** The genetics of polycystic ovary syndrome. *Am J Med.* **98(Suppl 1A) 1995; :9S–16S.**
- Legro, R.S., Spielman, R., Urbanek, M., Driscoll, D., Strauss, J.F., 3rd & Dunaif, A.** Phenotype and genotype in polycystic ovary syndrome. *Recent Prog Horm Res* **1998; 53: 217-256.**
- Legro R S, Kunselman A R, Dodson W C.** Prevalence and predictors for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome. A prospective study in 254 affected women. *J Clin Endocrinol Metab* **1999; 84 : 165 – 169.**
- Legro R S.** The genetics of obesity. Lessons for polycystic ovary syndrome. *Ann N.Y. Acad Sci* **2000; 900 : 193 – 202.**
- Legro RS, Urbanek M, Kunselman AR, Leiby BE, Dunaif A** Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated. *Fertil Steril* **2002; 78:51–57.**
- Legro RS.** Polycystic ovary syndrome and cardiovascular disease: a premature association? *Endocr Rev* **2003;24:302-312.**
- Legro RS, Castracane VD, Kauffman RP.** Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. *Obstet Gynecol Surv* **2004;59:141-154.**
- Leszezynski O E, Schafer R M, Perkis E G, Jerrell J P, and Kummerow F A.** Estrification of dehydroepiandrosterone by human plasma HDL3. *Bioch Biophys. Acta* **1989; 1014 : 90-97**
- Lewis GF, Uffelman KD, Szeto LW, et al.** Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. *Diabetes* **1993;42:833–42.**
- Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al.** Insulin resistance and insulin secretory dysfunction as precursors of non-insulindependent diabetes mellitus. Prospective studies of Pima Indians. *N Engl J Med* **1993; 329: 1988-92.**
- Lobo A, and Crang R L.** Elevation in un-bound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women

with polycystic ovarian disease. *J Clin Endocrinol Metab* 1981; 52 : 156.

Lobo R A, Paul W L, and Goebblsmann U. Dihydroepiandrosterone sulfate as an indicator of adrenal androgen function. *Obstet Gynecol* 1987; 57 : 69.

Lobo A, Kletzky O A, Campeau J D, and Dizerga G S. Elevated bioactive lutinizing hormone in women with Polycystic ovary syndrome. *Fertil Steril* 1983; 39 : 674.

Longcope C, and Williams K I H. The metabolism in normal women after pulse injection of H-estradiolo and H-estrone. *J Clin Endocrinol Metab* 1974; 38 : 602.

Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst *Rev* 2003;3:CD003053-CD003053.

Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary syndrome. *Fertil Steril* 1984;41:719–725.

Malmström R, Packard CJ, Watson TD, et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. *Arterioscler Thromb Vasc Biol* 1997;17:1454–64.

Mandarino, L.J., Wright, K.S., Verity, L.S., Nichols, J., Bell, J.M., Kolterman, O.G. & Beck- Nielsen, H. Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase. Evidence for their role in oxidative and nonoxidative glucose metabolism. *J Clin Invest* 1987; 80: 655-663.

Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metformin has direct effects on human ovarian steroidogenesis. *Fertil Steril* 2003;79:956-962.

Marsden P J, Murdoch A, Taylor R. Severe impairment of insulin action in adipocytes from amenorrheic subjects with polcystic ovary syndrome. *Metabolism* 1994; 43 : 1536–1542.

Martin K, Santoro N, Hall J. Management of ovulatory disorders with pusatile GnRh. *J Clin Endocrinol Metab* 1990; 71 : 181 A-181.

- Mather KJ, Verma S, Corenblum B, Anderson TJ.** Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 2000;85:1851-1856.
- Meigs JB, Wilson PWF, Nathan DM, D'Agostino RB, Williams K, Haffner SM .** Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. *Diabetes* 2003; 52:2160-7.
- McFarlane SI, Banerji M, Sowers JR.** Insulin resistance and cardiovascular disease. *J Clin Endocrinol Metab* 2001; 86 : 713 - 18
- McKenna T J.** Pathogenesis and treatment of Polycystic ovary syndrome. *N Engl J Med* 1988; 318 : 558 – 562.
- McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, et al.** Differentiation between obesity and insulin resistance in the association with C-reactive protein. *Circulation* 2002;106:2908-2912.
- McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G.** Use of metabolic markers to identify overweight individuals who are insulin resistant. *Ann Intern Med* 2003;139:802-809.
- Mitwally MF, Witchel SF, Casper RF.** Troglitazone: a possible modulator of ovarian steroidogenesis. *J Soc Gynecol Investig* 2002;9:163-167.
- Moggetti, P., Tosi, F., Castello, R., Magnani, C.M., Negri, C., Brun, E., Furlani, L., Caputo, M. & Muggeo, M.** The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. *J Clin Endocrinol Metab* 1996 b; 81: 952-960.
- Morabia A, Ross BM, Costanza MC, et al.** Population-based study of SR-BI genetic variation and lipid profile. *Atherosclerosis* 2004;175:159–68.
- Morales A J, Laughlin G A, Butzow T, Maheshwari H, Baumann G, Yen S S C.** Insulin, somatotrophic and LH axes in lean and obese women with polycystic ovary syndrome: common and distinct features. *J Clin Endocrinol Metab* 1996; 81 : 2854–2864.

Moran C, Knochelhauer E S, Boots L R. Adrenal androgen excess in hyperandrogenism: Relation to age and body mass. *Fertil Steril* 1999; **71** : 671 – 674.

Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;**88**:812-819

Mokdad AH, Ford ES, Bowman B. Prevalence of obesity, diabetes, and obesity-related health risk factors. *Jama* 2003; **289**: 76 - 79

Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. *Curr Opin Lipidol* 1999;**10**:321–7.

Nadir S H. Polycystic ovary syndrome and the androgen insulin connection. *Am J Obstet Gynecol* 1991; **165** : 346 – 348.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): *final report. Circulation* 2002;**106**:3143-3421.

Nelson VL, Qin KN, Rosenfield RL, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2001;**86**:5925-5933.

Nestler, J.E., Barlaschini, C.O., Matt, D.W., Steingold, K.A., Plymate, S.R., Clore, J.N. & Blackard, W.G. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1989; **68**: 1027-1032.

Nestler J E. Power L B, and Matt D W. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin level in obese women with PCOS. *J Clin Endocrinol Metab* 1992; **72** : 83.

Nestler JE. Insulin regulation of human ovarian androgens. *Hum Reprod* 1997; 12(suppl): 52-62.

Nestler, J.E., Jakubowicz, D.J., de Vargas, A.F., Brik, C., Quintero, N. & Medina, F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. *J Clin Endocrinol Metab* 1998 a; 83: 2001-2005.

Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. *Circulation* 2004;109:42–6.

Nobels F, Demailley D. Puberty and polycystic ovary syndrome: the insulin /insulin-like growth factor hypothesis. *Fertil Steril* 1992; 58: 655-663.

Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, Zidek W, Assmann G, Chun J, Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. *J Clin Invest* 2004; 113:569–581.

Normal RJ, Hague WM, Masters Sc, Wang XJ. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. *Hum Reprod* 1995; 10 : 2258 – 61.

Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. *Hum Reprod* 2001;16:1995-1998.

Ohisalo JJ, Stouffer JE. Adenosine, thyroid status and regulation of lipolysis. *Biochem J.* 1979; 178:249–251.

Ohisalo JJ, Ranta S, Huhtaniemi IT. Inhibition of adenosine 3',5'-monophosphate accumulation and lipolysis by adenosine analogs in human subcutaneous adipocytes. *J Clin Endocrinol Metab.* 1984; 58:32–35.

- Ohisalo JJ, Kaartinen JM, Ranta S, et al.** Weight loss normalized the inhibitory effect of N^6 -(phenylisopropyl)adenosine on lipolysis in fat cells of massively obese human subjects. *Clin Sci*. 1992; 83:589–592.
- Olefsky JM, Ciaraldi TP, Kolterman OG.** Mechanisms of insulin resistance in non-insulin-dependent (Type II) diabetes. *Am Med J*. 1985; 79(Suppl 3B):12–22.
- Orio F Jr, Palomba S, Cascella T.** Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2004;89:4588–4593.
- Orio F Jr, Palomba S, Spinelli L.** The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. *J Clin Endocrinol Metab* 2004;89:3696–3701.
- Packard CJ.** Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. *Biochem Soc Trans* 2003;31:1066–9.
- Paoletti A M, Cagnacci A, Soldani R.** Evidence that an altered prolactin release is consequent to abnormal ovarian activity in Polycystic ovary syndrome. *Fertil Steril* 1995; 64(6) : 1094.
- Paradisi G, Steinberg HO, Hempfling A.** Polycystic ovary syndrome is associated with endothelial dysfunction. *Circulation* 2001;103:1410–1415.
- Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD.** Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;88:576–580.
- Pasquali R, Casimirri F.** The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. *Clin Endocrinol (Oxf)* 1993;39:1–16.
- Pasquali R, Casimirri F, Venturoli S, Melchionda N.** Insulin resistance in patients with polycystic ovaries. *Acta Endocrinol* 1983; 104 : 110 – 116.

Pasquali R, Antenucci D, Casimirri F. Clinical and hormonal characteristic of obese amenorrheic hyperandrogenic women before and after weight loss. *J Clin Endocrinol Metab* 1989; 68 : 73 – 179.

Pasquali R, Casimirri F, Balestra V, Flamina R, Melchionda n, Barbara L. The relative contribution of androgens and insulin in determining abdominal fat distribution in premenopausal women. *J Clin Endocrinol Invest* 1991; 14 : 839.

Pasquali, R., Casimirri, F., Venturoli, S., Antonio, M., Morselli, L., Reho, S., Pezzoli, A. & Paradisi, R. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. *Metab Clin Exp* 1994 a; 13: 706- 713.

Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. *Circulation*.2002;106:1024–1028.

Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. *ArteriosclerThromb* 1992;12:1336–45.

Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ: Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol* 73:460–468, 1994.

Pearson TA, Blair SN, Daniels SR, et al. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. *Circulation*. 2002; 106: 388–391.

Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American

Heart Association. **Circulation.** 2003; 107: 499–511.

Peiris, A.N., Aiman, E.J., Drucker, W.D. & Kissebah, A.H. The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women. *J Clin Endocrinol Metab* 1989; 68: 715-720.

Pirwani I, Sattar N, Packard CJ, Wallace AM, Fleming R, Greer IA. Lipoprotein subfraction changes in women with oligomenorrhea: relationship to metabolic, hormonal and anthropometric indices. *J Soc Gynecol Invest* 1997; 4(suppl): 90A.

Polderman, K.H., Gooren, L.J., Asscheman, H., Bakker, A. & Heine, R.J. Induction of insulin resistance by androgens and estrogens. *J Clin Endocrinol Metab* 1994; 79: 265-271.

Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus -- a genetically programmed failure of the beta cell to compensate for insulin resistance. *N Engl J Med* 1996;334:777-783.

Polson D W, Adams J, Wadsworth J, Franks S. Polycystic ovaries -- a common finding in normal women. *Lancet* 1988; 1 : 870-872.

Poretsky, L., Cataldo, N.A., Rosenwaks, Z. & Giudice, L.C. The insulin-related ovarian regulatory system in health and disease. *Endocr Rev* 1999; 20: 535-582.

Prelevic GM, Wuzburger MI, Balint Pesic L, Nesic JS. Inhibitory effect of somatostatin on secretion of luteinising hormone and ovarian steroids in PCOS. *Lancet* 1990; 336 : 900 – 3.

Princen BHCMT, Romijn JA, Bisschop PH, et al. Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. *J Lipid Res* 2003;44:1341–8.

Rainwater DL, Mitchell BD, Mahaney MC, et al. Genetic relationship between measures of HDL phenotypes and insulin concentrations. *Arterioscler Thromb Vasc Biol* 1997;17:3414–19.

Raj S G, Thompson I E, and Taymor M C. Clinical aspects of polycystic ovary syndrome. *Gynecol* 1997; 439 : 552.

- Ravussin E, Valencia ME, Esparza J, et al.** Effects of a traditional lifestyle on obesity in Pima Indians. *Diabetes Care* 1994;17:1067–74.
- Reaven GM: Banting lecture:** Role of insulin resistance in human disease. *Diabetes* 1988; 37 : 1595 – 1607.
- Reaven GM.** Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. *Diabetes Care* 1991; 14:195–202.
- Reaven GM. Syndrome X. In: Becker KL, editor.** Principle and practice of endocrinology and metabolism. 3 ed. Philadelphia: *Lippicott Williams*, 2001: 1365-1369.
- Reaven GM.** The insulin resistance syndrome. *Curr Atheroscler Rep* 2003;5:364-371.
- Reaven G.** The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. *Endocrinol Metab Clin North Am* 2004;33:283-303.
- Rebuffe-Scrive M, Lonnroth P, Marin P, et al.** Regional adipose tissue metabolism in men and postmenopausal women. *Int J Obes* 1987;11:347–55.
- Rebuffe-Serive M, Gullberg G, and Lundburg P A.** Anthropometric variables And Metabolism in polycystic ovary disease. *Horm Metab. Res* 1988; 21 : 391 – 397.
- Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.** *Diabetes Care* 1997;20:1183-1197.
- Revised 2003 consensus on diagnostic criteria** and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 2004;19:41-47.
- Rincon, J., Holmang, A., Wahlstrom, E.O., Lonnroth, P., Bjorntorp, P., Zierath, J.R. & Wallberg- Henriksson, H.** Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. *Diabetes* 1996; 45: 615-621.
- Rittmaster R.** Treating hirsutism. *Endocrinologist* 1993;3:211–218.

- Robins SJ.** Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs high-density lipoprotein intervention trial. *Am J Cardiol* 2001;88:19–23N.
- Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, et al.** insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-Hit). *Diabetes Care* 2003;26:1513-1517.
- Robinson, S., Chan, S.P., Spacey, S., Anyaoku, V., Johnston, D.G. & Franks, S.** Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance [see comments]. *Clin Endocrinol* 1992; 36: 537-543.
- Rojanasakul A, Choilurkit L, Sirimongklkasem, Chaturachinda K.** Serum lipid in women with polycystic ovary syndrome with different body mass index. *Int J Obstet Gynecol* 1988; 27 : 401 – 406.
- Romualdi D, Guido M, Ciampelli M, et al.** Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. *Hum Reprod* 2003;18:1210-1218.
- Rosenfield R L, Barnes R B, Cara J F, and Lucky A W.** Disregulation of the cytochrome P450 C17 alpha as the case of polycystic ovary syndrome . *Fertil Steril* 1990; 53 :785.
- Rosner W.** An extraordinarily inaccurate assay for free testosterone is still with us. *J Clin Endocrinol Metab* 2001;86:2903.
- Rubins HB, Robins SJ, Collins D, Frye CL, Anderson JW, Elam WB, et al.** Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT). *N Engl J Med* 1999;341:410-418.
- Rust S, Rosier M, Funke H, et al.** Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat Genet* 1999;22:352–5.
- Ruutiaien K, Erkkola R, Gronroos M A.** Androgen parameters in hirsute women: Correlation with body mass index and age. *Fertil Steril* 1988; 50 : 255 – 259.

- Sacco RL, Benson RT, Kargman DE, et al.** High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan stroke study. *JAMA* 2001;285:2729–35.
- Sachalin-Jantti C.** Determinants of skeletal muscle glucose uptake in man with particular emphasis on glucose transport and glycogen synthesis. *Thesis, Monila OY, Helsinki.* 1995; 86.
- Sam S, Dunaif A.** Polycystic ovary syndrome: syndrome XX? *Trends Endocrinol Metab* 2003;14:365-370.
- Sara, V.R. & Hall, K.** Insulin-like growth factors and their binding proteins. *Physiol Rev* 1990; 70: 591-614.
- Saward L, Zahradka P.** Insulin is required for angiotensin II-mediated hypertrophy of smooth muscle cells. *Mol Cell Endocrinol* 1996; 122: 93-100.
- Sheuh W, Jeng C, Shieh S, Fuh M, Shen D, Chen Y.** Insulin resistance and abnormal electrocardiograms in patients with high blood pressure. *Am J Hypertens* 1992; 5 : 444 – 448.
- Senoz S, Ozaksit G, Turhan B, Gluek B, Gokmen O.** Lipid profiles in women with hirsutism and polycystic ovaries. *Gynecol Endocrinol* 1994; 8 : 33-37
- Sowers JR.** Obesity as a cardiovascular risk factor. *Am J Med* 2003; 115 (Suppl 8A): 37S-41S.
- Stein IL, Leventhal ML.** Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935;29:181-91.
- Silfen ME, Manibo AM, McMahon DJ, Levine LS, Murphy AR, Oberfield SE.** Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. *J Clin Endocrinol Metab* 2001;86:2863–2868.
- Simmons D, Thompson CF.** Prevalence of the metabolic syndrome among adult New Zealanders of Polynesian and European descent. *Diabetes Care* 2004;27:3002-3004.
- Smith G C, and Franks S.** Polycystic ovary syndrome. *Reproductive Medicine Review* 1993; 2 : 15 – 32.

Sniderman AD, Castro Cabezas M, Ribalta J, et al. A proposal to redefine familial combined hyperlipidaemia -- third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the scientific sessions of the European Society for Clinical Investigation. *Eur J Clin Invest* 2002;32:71–3.

Song J, Kim E, Shin C, Kim SS, Lee HK, Jung M, et al. Prevalence of the metabolic syndrome among South Korean adults: the Ansan study. *Diabet Med* 2004;21:1154-1155.

Sowers J R. Insulin resistance, hyperinsulinemia, dyslipidemia and accelerated atherosclerosis. *J Clin Endocrinol Metab* 1992; 32 : 529 – 535.

Speroff L, Glass R H, and Kase N G. Amenorrhea in clinical Gynecology and Infertility. *Fifth edition. Williams and Wilkins-UK 1994 "a" 401 456.*

Speroff L, Glass R H, and Kase N G. Anovulation and the polycystic ovaries. In clinical Gynecology and Endocrinology and Infertility. Fifth edition. *Williams and Wilkins-UK 1994 "b" 483 – 513.*

Speroff L J, Kase N G, and Glass R H. Insulin like growth factor 1 and 2 and their binding proteins. *Clinical gynecologic endocrinology and infertility 1999; Lippincott Williams & Wilkins, USA : 398 – 400.*

Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. *Fertil Steril* 2004;81:630-637.

Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935; 29: 181 – 191.

Steinberger J, Daniels SR, for American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young); American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease

in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). *Circulation* 2003;107:1448–53.

Sturat C A, Prince M J, Peters E, and Meyers W J. Hyperinsulinemia and hyperandrogenism. In-Vivo response to insulin infusion. *Obstet Gynecol* 1987; 69 : 921 – 925.

Tai ES, Goh SY, Lee JJ, Wong MS, Hang D, Hughes K, et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. *Diabetes Care* 2004;27:1728-1734.

Taira K, Hikita M, Kobayashi J, et al. Delayed post-prandial lipid metabolism in subjects with intra-abdominal visceral fat accumulation. *Eur J Clin Invest* 1999;29:301–8.

Takai I, Tau S, Takakura K, and Mari T. The three types of polycystic ovarian disease in relation to androgenic function. *Fertil Steril* 1991; 56 : 5 – 856.

Talbott EO, Zborowskii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. *Minerva Ginecol* 2004;56:27-39.

Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. *Arterioscler Thromb Vasc Biol* 1995;15:821–826.

Tanabo K, Saglian P, and Channing C P. Levels of inhibin E activity and steroids in human follicular fluid from women with PCOD. *J Clin Endocrinol Metab* 1983; 57 :24.

Taylor A E. Polycystic ovary syndrome. *Endocrinal Metab Clin North Am* 1998; 27 : 877-902.

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. *Fertil Steril* 2004 81; 19- 25

Third Report of the National Cholesterol Education Program (NCEP) . Expert panel on detection, evaluation, and treatment of

high blood cholesterol in adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106:3143–3421.

Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. *J Lipid Res* 1996;37:439–47.

Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation*. 2003; 107: 3109–3116.

Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. *Proc Nutr Soc* 2004 ; 60 : 329 - 39

Tuan C-Y, Abbasi F, Lamendola C, McLaughlin T, Reaven G. Usefulness of plasma glucose and insulin concentrations in identifying patients with insulin resistance. *Am J Cardiol* 2003;92:606-610.

Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343-1350.

US Department of Agriculture and US Department of Health and Human Services. Nutrition and Your Health: Dietary Guidelines for Americans. 5th ed. Home and Garden Bulletin No. 232. *Washington, DC: US Department of Agriculture; 2000.*

Uwaifo GI, Ratner RE. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. *Am J Med* 2003; 115 (Suppl 8A): 12S-19S.

Vaitukaitis J L. Polycystic ovary syndrome. *N Engl J* 1988; *Med* 309 : 1245 – 1250.

Van Santbrink E J, Hop W C, and Fause B C. Classification of normogonadotropic infertility: Polycystic ovaries diagnosed of U/S

versus endocrine characteristics of polycystic ovary syndrome. *Fertil Steril* 1997; 67 : 452-458.

Velazquez EM, Mendoza SG, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia and systolic blood pressure, while facilitating normal menses and pregnancy. *Metabolism* 1994; 43: 647-654..

Vollenhoven B, Clark S, Kovacs G, Burger H, Healy D. Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins. *Aust N Z J Obstet Gynaecol* 2000;40:54-8.

Vermuler M, and Kletzky O A. Longitudinal evaluation of the luteal phase and its transition into the follicular phase. *J Clin Endocrinol Metab* 1979; 33 : 759.

Vernon RG, Finley E, Taylor E. Adenosine and the control of lipolysis in rat adipocytes during pregnancy and lactation. *Biochem J.* 1983; 216:121–128.

Vinicor F . Is diabetes a public-health disorder? *Diabetes Care* 1994;17 (suppl 1) :22–7.

Voutilainen, R., Franks, S., Mason, H.D. & Martikainen, H. Expression of insulin-like growth factor (IGF), IGF-binding protein, and IGF receptor messenger ribonucleic acids in normal and polycystic ovaries. *J Clin Endocrinol Metab* 1996; 81: 1003-1008.

Vrbikova J, Vondra K, Cicula D, Dvorakova K, Stanicka S, Sramkova D. Metabolic syndrome in Czech women with polycystic ovary syndrome. *Hum Reprod* 2005; 20 : 3328 – 32.

Vural B et al. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. *Hum Reprod* 2005; 20: 2409–2413

Wang J, Thornton JC, Bari S, Williamson B, Gallagher D, Heymsfield SB, et al. Comparisons of waist circumferences measured at 4 sites. *Am J Clin Nutr* 2003;77:379-384.

- Weiss R, Dziuna J, Birgert TS, Tamborlane WV, Taksali SF, Yeckel CW, et al.** Obesity and the metabolic syndrome in children and adolescents. *N Eng J Med* 2004;350:2362-2374.
- White, M.F.** The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. *Recent Prog Horm Res* 1998; 53: 119-138.
- White D M, Leigh A, Wilson C, Donaldson A, and Franks S.** Gonadotropins and gonadal steroids response to a single dose of a long-acting agonist of gonadotropin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 1995; 42 : 478 – 481.
- WHO** expert consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363:157-163.
- Whitesell RR, Gliemann J.** Kinetic parameters of 3-O-methylglucose and glucose in adipocytes. *J Biol Chem.* 1979; 254:5276–5283.
- Wiesenthal, S.R., Sandhu, H., McCall, R.H., Tchipashvili, V., Yoshii, H., Polonsky, K., Shi, Z.Q., Lewis, G.F., Mari, A. & Giacca, A.** Free fatty acids impair hepatic insulin extraction in vivo [published erratum appears in Diabetes 1999 Jun;48(6):1348]. *Diabetes* 1999; 48: 766-774.
- Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB.** Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 1985;61:946–951.
- Wild R A, and Bartholomew M J.** The influence of body weight on lipoprotein lipid in patients with polycystic ovary syndrome. *Am J Obstet Gynecol* 1988; 19 : 423 – 427.
- Wild RA, Aplebaum-Bowden D, Demers LM.** Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgen. *Clin Chem.* 1990; 36:283–289.
- Wild R A, Guib B, Hartz A, Demers L M, Richard J.** Clinical signs of androgen excess as a risk factors for coronary artery disease. *Fertil Steril* 1990; 54 : 255.

- Wild R A.** Lipid metabolism and hyperandrogenism. *Clin Obstet Gynecol* 1991; 34 : 797 – 871.
- Wild R.** Metabolic aspects of polycystic ovary syndrome. *Semin Reprod Endocrinol* 1997; 15: 105-110.
- Wild S, Pierpoint T, Jacobs H, McKeigue P.** Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. *Hum Fertil (Camb)* 2000;3:101-105.
- Wilson PW, Grundy SM.** The metabolic syndrome: practical guide to origins and treatment: part I. *Circulation* 2003;108:1422–4.
- World Health Organization.** Definition, diagnosis, and classification of diabetes mellitus and its S192 *J Med Assoc Thai Vol. 87 Suppl. 3* 2004 complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. *WHO, Geneva* 1999.
- Wu X, Chang Z, Su Y, Chang Hua Chan Ko, Tsa Chih.** Chinese *Journal of Obstetric and gynecology* 1998.
- Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK.** The dexamethasone-suppressed corticotropin-releasing hormone stimulation test differentiates mild Cushing's disease from normal physiology. *J Clin Endocrinol Metab* 1998;83:348–352.
- Yen S S C.** The polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 1980; 12:177–207.
- Yen S S C.** Chronic anovulation cause by peripheral endocrine disorders In Yen S S C, Jaffe B R, (eds). *Reproductive Endocrinology. Philadelphia W B. Saunders* 1991; 576 – 630.
- Yen, S.C.C., Jaffe, R.B. & Barbieri, R.L.** Polycystic Ovary Syndrome (Hyperandrogenic Chronic Anovulation). in: *Reproductive Endocrinology. Physiology, pathophysiology and clinical management. W. B. Saunders Company: 1999; 436-478.*
- Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM.** Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. *Diabetes Care* 2000;23:171-175.

- Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M.** Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. *J Clin Endocrinol Metab* 2002;87:3871-3875.
- Yki-Jarvinen H.** Insulin resistance and endothelial dysfunction. *Best Pract Res Clin Endocrinol Metab* 2003; 17: 411-30.
- Yki-Jarvinen H, Kubo K, Zawadzki J, et al.** Dissociation of *in vitro* sensitivities of glucose transport and antilipolysis to insulin in NIDDM. *Am J Physiol.* 1987; 253:E300–E304.
- Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, Tahara H, Shoji T, Okuno Y, Nishizawa Y.** Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. *Diabetes Care* 2003;26:2426–2432.
- Zavaroni I, Mazza S, Dall’Aglio E, Gasparini P, Passeri M, Reaven GM.** Prevalence of hyperinsulinaemia in patients with high blood pressure. *J Intern Med* 1992;231:235-240.
- Zawadzki J K, Dunaif A.** Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F P; et al (eds) 1992; polycystic ovarian syndrome : Current issue in Endocrinology and Metabolism, Vol 4, Boston *Blackwell Scientific*, 1992; pp 377 – 384.
- Zimmermann S, Phillips RA, Dunaif A.** Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. *J Clin Endocrinol Metab* 1992;75:508-513.
- Report of the Expert Committee** on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997 ; 20:1183–1197